Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

EGFR negative + ALK negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

ALK positive (74)

EGFR expression (46)

EGFR overexpression (34)

EGFR positive (8)

EGFR negative (6)

ALK negative (4)

EGFR expression + ALK positive (3)

EGFRVIII expression + PTEN expression (3)

EGFRvIII expression (3)

EGFR expression + MET expression (2)

EGFR overexpression + HER-2 overexpression (2)

MMP17 expression + EGFR expression + RB1 expression (2)

MUC1 expression + EGFR expression (2)

TROP2 expression + EGFR expression (2)

EGFR expression + HER-2 expression (1)

EGFR underexpression (1)

EGFRVIII overexpression (1)

EPHA2 overexpression + EGFR overexpression (1)

GPC3 positive + EGFR expression (1)

ALK expression + PDGFRA expression (1)

ALK expression + PDGFRB expression (1)

ALK overexpression (1)

ALK positive + ROS1 positive (1)

ALK positive + YAP1 overexpression (1)

ALK positive + YES1 overexpression (1)

KRT7 positive + NKX2-1 positive + ALK overexpression (1)

DRD2 expression + EGFR overexpression (0)

YAP1 overexpression + EGFR overexpression (0)

ALK positive (74)

EGFR expression (46)

EGFR overexpression (34)

EGFR positive (8)

EGFR negative (6)

ALK negative (4)

EGFR expression + ALK positive (3)

EGFRVIII expression + PTEN expression (3)

EGFRvIII expression (3)

EGFR expression + MET expression (2)

EGFR overexpression + HER-2 overexpression (2)

MMP17 expression + EGFR expression + RB1 expression (2)

MUC1 expression + EGFR expression (2)

TROP2 expression + EGFR expression (2)

EGFR expression + HER-2 expression (1)

EGFR underexpression (1)

EGFRVIII overexpression (1)

EPHA2 overexpression + EGFR overexpression (1)

GPC3 positive + EGFR expression (1)

ALK expression + PDGFRA expression (1)

ALK expression + PDGFRB expression (1)

ALK overexpression (1)

ALK positive + ROS1 positive (1)

ALK positive + YAP1 overexpression (1)

ALK positive + YES1 overexpression (1)

KRT7 positive + NKX2-1 positive + ALK overexpression (1)

DRD2 expression + EGFR overexpression (0)

YAP1 overexpression + EGFR overexpression (0)

›

EGFR negative + ALK negative	Non Small Cell Lung Cancer	EGFR negative + ALK negative	Non Small Cell Lung Cancer	OSE 2101 Sensitive: B - Late Trials OSE 2101 Sensitive : B	OSE 2101 Sensitive: B - Late Trials OSE 2101 Sensitive : B
EGFR negative + ALK negative	Lung Non-Squamous Non-Small Cell Cancer	EGFR negative + ALK negative	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3	sintilimab + fruquintinib Sensitive: C3 – Early Trials sintilimab + fruquintinib Sensitive : C3
EGFR negative + ALK negative	Non Small Cell Lung Cancer	EGFR negative + ALK negative	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
EGFR negative + ALK negative	Non Small Cell Lung Cancer	EGFR negative + ALK negative	Non Small Cell Lung Cancer	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3	recombinant human endostatin Sensitive: C3 – Early Trials recombinant human endostatin Sensitive : C3